A carregar...
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
Sorafenib has become the only FDA‐approved first‐line therapy for advanced hepatocellular carcinoma (HCC) for more than 10 years, but there is still no validated predictive or prognostic marker. Peptidase inhibitor 16 (PI16) is a functionally unknown gene in cancer research. This study aimed to dete...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7541153/ https://ncbi.nlm.nih.gov/pubmed/32779397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3331 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|